Bibliography for MD7009/MD7259 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies BETA

[1]

Amori, R.E. et al. 2007. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. JAMA. 298, 2 (Jul. 2007). DOI:https://doi.org/10.1001/jama.298.2.194.

[2]

Amy Kennedy 2013. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. PLoS ONE. 8, 3 (2013). DOI:https://doi.org/doi:  10.1371/journal.pone.0058861.

[3]

Anderson, B. et al. 2005. The art of empowerment: stories and strategies for diabetes educators. American Diabetes Association.

[4]

Anthony H. Barnett, Jenny Grice 2013. New Mechanisms in Glucose Control. BMJ Books; 1 edition.

[5]

Ashwell, S.G. et al. 2006. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine. 23, 3 (Mar. 2006), 285–292. DOI:https://doi.org/10.1111/j.1464-5491.2005.01781.x.

[6]

Atkinson, M.A. 2012. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. 2, 11 (Nov. 2012), a007641–a007641. DOI:https://doi.org/10.1101/cshperspect.a007641.

[7]

Avery, L. et al. 2012. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care. 35, 12 (Dec. 2012), 2681–2689. DOI:https://doi.org/10.2337/dc11-2452.

[8]

Bailey, C.J. et al. 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet. 375, 9733 (Jun. 2010), 2223–2233. DOI:https://doi.org/10.1016/S0140-6736(10)60407-2.

[9]

Barry, V.W. et al. 2014. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. Progress in Cardiovascular Diseases. 56, 4 (Jan. 2014), 382–390. DOI:https://doi.org/10.1016/j.pcad.2013.09.002.

[10]

Bennett, W.L. et al. 2011. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Annals of Internal Medicine. 154, 9 (May 2011). DOI:https://doi.org/10.7326/0003-4819-154-9-201105030-00336.

[11]

Bethel, M.A. et al. 2017. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). Diabetes Care. (Jan. 2017). DOI:https://doi.org/10.2337/dc16-1135.

[12]

Beverley M Shields 2015. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open. 5, 11 (2015). DOI:https://doi.org/doi:  10.1136/bmjopen-2015-009088.

[13]

Birkeland, K.I. 2015. Hyperglycaemia in pregnancy: still a lot to learn. The Lancet Diabetes & Endocrinology. 3, 10 (Oct. 2015), 752–753. DOI:https://doi.org/10.1016/S2213-8587(15)00282-X.

[14]

Bretzel, R.G. et al. 2008. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet. 371, 9618 (Mar. 2008), 1073–1084. DOI:https://doi.org/10.1016/S0140-6736(08)60485-7.

[15]

Brown, J. et al. 1996. Lifestyle interventions for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[16]

Buse, J.B. et al. 2010. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 33, 6 (Jun. 2010), 1255–1261. DOI:https://doi.org/10.2337/dc09-1914.

[17]

Buse, J.B. et al. 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet. 374, 9683 (Jul. 2009), 39–47. DOI:https://doi.org/10.1016/S0140-6736(09)60659-0.

[18]

Buse, J.B. et al. 2011. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine. 154, 2 (Jan. 2011). DOI:https://doi.org/10.7326/0003-4819-154-2-201101180-00300.

[19]

Capehorn, M. et al. 2017. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia                              ). Diabetic Medicine. (Mar. 2017). DOI:https://doi.org/10.1111/dme.13357.

[20]

Carver, C. 2006. Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. The Diabetes Educator. 32, 6 (Nov. 2006), 910–917. DOI:https://doi.org/10.1177/0145721706294259.

[21]

Celia G. Walker 2015. Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk. PLoS ONE. 10, 7 (2015). DOI:https://doi.org/doi:  10.1371/journal.pone.0131681.

[22]

Chatterjee, S. and Davies, M. 2015. Type 2 diabetes: recent advances in diagnosis and management. Prescriber. 26, 10 (May 2015), 15–21. DOI:https://doi.org/10.1002/psb.1355.

[23]

Chimen, M. et al. 2012. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 55, 3 (Mar. 2012), 542–551. DOI:https://doi.org/10.1007/s00125-011-2403-2.

[24]

Choudhary, P. et al. 2012. Islet cell transplantation: current status in the UK (2012). Practical Diabetes. 29, 7 (Sep. 2012), 280–285. DOI:https://doi.org/10.1002/pdi.1707.

[25]

Copeland, K.C. et al. 2013. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. PEDIATRICS. 131, 2 (Feb. 2013), 364–382. DOI:https://doi.org/10.1542/peds.2012-3494.

[26]

Courtney, H. et al. 2017. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Volume 10, (Mar. 2017), 79–87. DOI:https://doi.org/10.2147/DMSO.S126763.

[27]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[28]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[29]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[30]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[31]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[32]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[33]

Daly, H. et al. 2015. Development of a self-management education module for those with type 2 diabetes on injectable therapies. Practical Diabetes. 32, 8 (Oct. 2015), 305–310a. DOI:https://doi.org/10.1002/pdi.1979.

[34]

Davies, M. et al. 2005. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care. 28, 6 (Jun. 2005), 1282–1288. DOI:https://doi.org/10.2337/diacare.28.6.1282.

[35]

Davies, M. et al. 2017. Introduction of biosimilar insulins in Europe. Diabetic Medicine. 34, 10 (Oct. 2017), 1340–1353. DOI:https://doi.org/10.1111/dme.13400.

[36]

Davies, M.J. et al. 2008. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 336, 7642 (Mar. 2008), 491–495. DOI:https://doi.org/10.1136/bmj.39474.922025.BE.

[37]

Davies, M.J. and Chatterjee, S. 2017. Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. Nature Reviews Endocrinology. 13, 6 (Apr. 2017), 317–318. DOI:https://doi.org/10.1038/nrendo.2017.41.

[38]

Deacon, C.F. and Lebovitz, H.E. 2016. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism. 18, 4 (Apr. 2016), 333–347. DOI:https://doi.org/10.1111/dom.12610.

[39]

Dhatariya, K.K. et al. 2017. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabetic Medicine. 34, 10 (Oct. 2017), 1361–1366. DOI:https://doi.org/10.1111/dme.13427.

[40]

Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet. 375, 9733 (Jun. 2010), 2234–2243. DOI:https://doi.org/10.1016/S0140-6736(10)60406-0.

[41]

Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet. 375, 9733 (Jun. 2010), 2234–2243. DOI:https://doi.org/10.1016/S0140-6736(10)60406-0.

[42]

Dungan, K.M. et al. 2014. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet. 384, 9951 (Oct. 2014), 1349–1357. DOI:https://doi.org/10.1016/S0140-6736(14)60976-4.

[43]

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials- ClinicalKey: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null.

[44]

Evans, M. et al. 2011. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism. 13, 8 (Aug. 2011), 677–684. DOI:https://doi.org/10.1111/j.1463-1326.2011.01395.x.

[45]

Frandsen, C.S.S. and Madsbad, S. 2014. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine. 31, 11 (Nov. 2014), 1293–1300. DOI:https://doi.org/10.1111/dme.12561.

[46]

Funnell, M.M. 2007. Overcoming Barriers to the Initiation of Insulin Therapy. Clinical Diabetes. 25, 1 (Jan. 2007), 36–38. DOI:https://doi.org/10.2337/diaclin.25.1.36.

[47]

Gallwitz, B. et al. 2012. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet. 380, 9840 (Aug. 2012), 475–483. DOI:https://doi.org/10.1016/S0140-6736(12)60691-6.

[48]

Garber, A.J. et al. 2006. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism. 8, 1 (Jan. 2006), 58–66. DOI:https://doi.org/10.1111/j.1463-1326.2005.00563.x.

[49]

Garber, A.J. et al. 2012. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet. 379, 9825 (Apr. 2012), 1498–1507. DOI:https://doi.org/10.1016/S0140-6736(12)60205-0.

[50]

Garber, A.J. et al. 2007. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism. 9, 5 (Sep. 2007), 630–639. DOI:https://doi.org/10.1111/j.1463-1326.2006.00654.x.

[51]

Gough, S.C.L. 2007. A review of human and analogue insulin trials. Diabetes Research and Clinical Practice. 77, 1 (Jul. 2007), 1–15. DOI:https://doi.org/10.1016/j.diabres.2006.10.015.

[52]

Gough, S.C.L. et al. 2013. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes, Obesity and Metabolism. 15, 4 (Apr. 2013), 301–309. DOI:https://doi.org/10.1111/dom.12052.

[53]

Grammes, J. et al. 2017. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic Medicine. (Aug. 2017). DOI:https://doi.org/10.1111/dme.13506.

[54]

Gray, L.J. et al. 2014. External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice. 104, 3 (Jun. 2014), 451–458. DOI:https://doi.org/10.1016/j.diabres.2014.03.018.

[55]

Gray, L.J. et al. 2012. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia. 55, 12 (Dec. 2012), 3238–3244. DOI:https://doi.org/10.1007/s00125-012-2725-8.

[56]

Green, J.B. et al. 2015. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 373, 3 (Jul. 2015), 232–242. DOI:https://doi.org/10.1056/NEJMoa1501352.

[57]

Gururaj Setty, S. et al. 2016. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal. 92, 1085 (Mar. 2016), 152–164. DOI:https://doi.org/10.1136/postgradmedj-2015-133716.

[58]

Gururaj Setty, S. et al. 2016. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal. 92, 1085 (Mar. 2016), 152–164. DOI:https://doi.org/10.1136/postgradmedj-2015-133716.

[59]

Hadjiconstantinou, M. et al. 2016. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research. 18, 10 (Oct. 2016). DOI:https://doi.org/10.2196/jmir.5991.

[60]

Hartman, Y.A.W. et al. 2017. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care. 40, 9 (Sep. 2017), e120–e121. DOI:https://doi.org/10.2337/dc17-0787.

[61]

Heinonen, I. et al. 2013. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. BMJ Open. 3, 6 (May 2013). DOI:https://doi.org/10.1136/bmjopen-2013-002901.

[62]

Heller, S.R. et al. 2004. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine. 21, 7 (Jul. 2004), 769–775. DOI:https://doi.org/10.1111/j.1464-5491.2004.01244.x.

[63]

Henson, Joseph 2014. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. (Nov. 2014).

[64]

Hermansen, K. et al. 2006. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care. 29, 6 (Jun. 2006), 1269–1274. DOI:https://doi.org/10.2337/dc05-1365.

[65]

Holman, R.R. et al. 2007. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine. 357, 17 (Oct. 2007), 1716–1730. DOI:https://doi.org/10.1056/NEJMoa075392.

[66]

Holman, R.R. and Turner, R.C. 1985. A Practical Guide to Basal and Prandial Insulin Therapy. Diabetic Medicine. 2, 1 (Jan. 1985), 45–53. DOI:https://doi.org/10.1111/j.1464-5491.1985.tb00592.x.

[67]

Home, P.D. 2012. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism. 14, 9 (Sep. 2012), 780–788. DOI:https://doi.org/10.1111/j.1463-1326.2012.01580.x.

[68]

Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[69]

Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[70]

Htike, Z.Z. et al. 2017. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 19, 4 (Apr. 2017), 524–536. DOI:https://doi.org/10.1111/dom.12849.

[71]

Htike, Z.Z. et al. 2017. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 19, 4 (Apr. 2017), 524–536. DOI:https://doi.org/10.1111/dom.12849.

[72]

Htike, Z.Z. et al. 2016. Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. British Journal of Diabetes. 16, 3 (Sep. 2016). DOI:https://doi.org/10.15277/bjd.2016.091.

[73]

Inzucchi, S.E. et al. 2015. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38, 1 (Jan. 2015), 140–149. DOI:https://doi.org/10.2337/dc14-2441.

[74]

Ismail-Beigi, F. 2012. Glycemic Management of Type 2 Diabetes Mellitus. New England Journal of Medicine. 366, 14 (Apr. 2012), 1319–1327. DOI:https://doi.org/10.1056/NEJMcp1013127.

[75]

John M Jakicic 2005. Physical activity considerations for the treatment and prevention of obesity. The American Journal of Clinical Nutrition. 82, 1 (Jan. 2005), 226S-229S.

[76]

Johnston, B.C. et al. 2014. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA. 312, 9 (Sep. 2014). DOI:https://doi.org/10.1001/jama.2014.10397.

[77]

Jones, A.G. and Hattersley, A.T. 2013. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine. 30, 7 (Jul. 2013), 803–817. DOI:https://doi.org/10.1111/dme.12159.

[78]

Kamlesh Khunti 2015. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE. 10, 9 (2015). DOI:https://doi.org/doi:  10.1371/journal.pone.0135702.

[79]

Kenneth Hodson 2010. Gestational diabetes: emerging concepts in pathophysiology. Obstetric Medicine. 3, 4 (2010). DOI:https://doi.org/doi:  10.1258/om.2010.100025.

[80]

Latika Sahu 2009. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. Obstetric Medicine. 2, 4 (2009). DOI:https://doi.org/doi:  10.1258/om.2009.080049.

[81]

Lee, I.-M. 2010. Physical Activity and Weight Gain Prevention. JAMA. 303, 12 (Mar. 2010). DOI:https://doi.org/10.1001/jama.2010.312.

[82]

Leff, D.R. and Heath, D. 2009. Surgery for obesity in adulthood. BMJ. 339, sep22 1 (Sep. 2009), b3402–b3402. DOI:https://doi.org/10.1136/bmj.b3402.

[83]

Levin, P.A. et al. 2017. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Volume 10, (Apr. 2017), 123–139. DOI:https://doi.org/10.2147/DMSO.S130834.

[84]

Mäkimattila, S. et al. 1999. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 42, 4 (Mar. 1999), 406–412. DOI:https://doi.org/10.1007/s001250051172.

[85]

Marre, M. et al. 2009. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine. 26, 3 (Mar. 2009), 268–278. DOI:https://doi.org/10.1111/j.1464-5491.2009.02666.x.

[86]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 311–322. DOI:https://doi.org/10.1056/NEJMoa1603827.

[87]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 311–322. DOI:https://doi.org/10.1056/NEJMoa1603827.

[88]

Marso, S.P. et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 375, 19 (Nov. 2016), 1834–1844. DOI:https://doi.org/10.1056/NEJMoa1607141.

[89]

Merlin C. Thomas 2016. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy. 7, 3 (2016). DOI:https://doi.org/doi:  10.1007/s13300-016-0189-4.

[90]

Michael Riddell 2009. Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. Journal of diabetes science and technology (Online). 3, 4 (2009). DOI:https://doi.org/doi:  10.1177/193229680900300439.

[91]

Min, S.H. et al. 2017. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews. 33, 1 (Jan. 2017). DOI:https://doi.org/10.1002/dmrr.2818.

[92]

Mishriky, B.M. et al. 2015. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 109, 2 (Aug. 2015), 378–388. DOI:https://doi.org/10.1016/j.diabres.2015.05.025.

[93]

Mishriky, B.M. et al. 2015. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 109, 2 (Aug. 2015), 378–388. DOI:https://doi.org/10.1016/j.diabres.2015.05.025.

[94]

Moreno-Castilla, C. et al. 2016. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. Current Diabetes Reports. 16, 4 (Apr. 2016). DOI:https://doi.org/10.1007/s11892-016-0717-7.

[95]

Nathan, D.M. et al. 2006. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 29, 8 (Aug. 2006), 1963–1972. DOI:https://doi.org/10.2337/dc06-9912.

[96]

Nauck, M. et al. 2014. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care. 37, 8 (Aug. 2014), 2149–2158. DOI:https://doi.org/10.2337/dc13-2761.

[97]

Nauck, M. 2016. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism. 18, 3 (Mar. 2016), 203–216. DOI:https://doi.org/10.1111/dom.12591.

[98]

Nauck, M.A. et al. 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism. 9, 2 (Mar. 2007), 194–205. DOI:https://doi.org/10.1111/j.1463-1326.2006.00704.x.

[99]

Nauck, M.A. and Meier, J.J. 2016. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology. 4, 6 (Jun. 2016), 525–536. DOI:https://doi.org/10.1016/S2213-8587(15)00482-9.

[100]

Nissen, S.E. and Wolski, K. 2007. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine. 356, 24 (Jun. 2007), 2457–2471. DOI:https://doi.org/10.1056/NEJMoa072761.

[101]

Nolan, C.J. et al. 2015. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes. 64, 3 (Mar. 2015), 673–686. DOI:https://doi.org/10.2337/db14-0694.

[102]

Paul Craddy 2014. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy. 5, 1 (2014). DOI:https://doi.org/doi:  10.1007/s13300-014-0061-3.

[103]

Persaud, S.J. and Jones, P.M. 2016. A Wake-up Call for Type 2 Diabetes? New England Journal of Medicine. 375, 11 (Sep. 2016), 1090–1092. DOI:https://doi.org/10.1056/NEJMcibr1607950.

[104]

Postnatal testing following gestational diabetes- ClinicalKey: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null.

[105]

Qin, L. et al. 2010. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. European Journal of Epidemiology. 25, 1 (Jan. 2010), 5–12. DOI:https://doi.org/10.1007/s10654-009-9395-y.

[106]

Raskin, P. et al. 2005. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 28, 2 (Feb. 2005), 260–265. DOI:https://doi.org/10.2337/diacare.28.2.260.

[107]

Resources and tools: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html.

[108]

Resources and tools: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html.

[109]

Resources and tools: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html.

[110]

Richard I. G. Holt, ,  Clive Cockram, ,  Allan Flyvbjerg, , and  Barry J. Goldstein 2016. Textbook of Diabetes. John Wiley.

[111]

Richter, B. and Neises, G. 1996. ‘Human’ insulin versus animal insulin in people with diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[112]

Riddle, M.C. et al. 2013. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 36, 9 (Sep. 2013), 2489–2496. DOI:https://doi.org/10.2337/dc12-2454.

[113]

Rinki Murphy 2015. Monogenic diabetes and pregnancy. Obstetric Medicine. 8, 3 (2015). DOI:https://doi.org/doi:  10.1177/1753495X15590713.

[114]

Rizos, C.V. et al. 2016. The current role of thiazolidinediones in diabetes management. Archives of Toxicology. 90, 8 (Aug. 2016), 1861–1881. DOI:https://doi.org/10.1007/s00204-016-1737-4.

[115]

Rosenstock, J. et al. 2008. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 51, 3 (Mar. 2008), 408–416. DOI:https://doi.org/10.1007/s00125-007-0911-x.

[116]

Rosenstock, J. et al. 2013. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 36, 10 (Oct. 2013), 2945–2951. DOI:https://doi.org/10.2337/dc12-2709.

[117]

Rotz, M.E. et al. 2015. Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice. 69, 5 (May 2015), 531–549. DOI:https://doi.org/10.1111/ijcp.12572.

[118]

Ryder, B. et al. 2013. ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes. 30, 9 (Nov. 2013), 388–391. DOI:https://doi.org/10.1002/pdi.1816.

[119]

S M Attard 2015. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes. 5, 6 (2015). DOI:https://doi.org/doi:  10.1038/nutd.2015.16.

[120]

Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com: http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level.

[121]

Sallis, J.F. et al. 2016. Progress in physical activity over the Olympic quadrennium. The Lancet. 388, 10051 (Sep. 2016), 1325–1336. DOI:https://doi.org/10.1016/S0140-6736(16)30581-5.

[122]

Samuel, V.T. and Shulman, G.I. 2012. Intergrating Mechanisms  for Insulin Resistance: Common Threads and Missing Links. Cell. 148, 5 (Mar. 2012), 852–871. DOI:https://doi.org/10.1016/j.cell.2012.02.017.

[123]

Schauer, P.R. et al. 2017. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine. 376, 7 (Feb. 2017), 641–651. DOI:https://doi.org/10.1056/NEJMoa1600869.

[124]

Schauer, P.R. et al. 2012. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine. 366, 17 (Apr. 2012), 1567–1576. DOI:https://doi.org/10.1056/NEJMoa1200225.

[125]

Schauer, P.R. et al. 2012. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine. 366, 17 (Apr. 2012), 1567–1576. DOI:https://doi.org/10.1056/NEJMoa1200225.

[126]

Schwartz, S.S. et al. 2016. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care. 39, 2 (Feb. 2016), 179–186. DOI:https://doi.org/10.2337/dc15-1585.

[127]

Simmons, R.K. et al. 2016. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Health Technology Assessment. 20, 64 (Aug. 2016), 1–86. DOI:https://doi.org/10.3310/hta20640.

[128]

Sivasubramaniyam, S. et al. 2017. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine. 34, 10 (Oct. 2017), 1456–1460. DOI:https://doi.org/10.1111/dme.13438.

[129]

Sjöström, L. et al. 2004. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. New England Journal of Medicine. 351, 26 (Dec. 2004), 2683–2693. DOI:https://doi.org/10.1056/NEJMoa035622.

[130]

Srinivasan, B.T. et al. 2008. Recent advances in the management of type 2 diabetes mellitus: a review. Postgraduate Medical Journal. 84, 996 (Oct. 2008), 524–531. DOI:https://doi.org/10.1136/pgmj.2008.067918.

[131]

Srinivasan, B.T. and Davies, M. 2014. Glycaemic management of type 2 diabetes. Medicine. 42, 12 (Dec. 2014), 711–717. DOI:https://doi.org/10.1016/j.mpmed.2014.09.011.

[132]

Srinivasan, P. et al. 2007. Islet cell transplantation. Postgraduate Medical Journal. 83, 978 (Apr. 2007), 224–229. DOI:https://doi.org/10.1136/pgmj.2006.053447.

[133]

Steven, S. et al. 2016. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care. 39, 5 (May 2016), 808–815. DOI:https://doi.org/10.2337/dc15-1942.

[134]

Steven, S. and Taylor, R. 2015. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabetic Medicine. 32, 9 (Sep. 2015), 1149–1155. DOI:https://doi.org/10.1111/dme.12722.

[135]

Stewart, Z.A. et al. 2016. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine. 375, 7 (Aug. 2016), 644–654. DOI:https://doi.org/10.1056/NEJMoa1602494.

[136]

Swinnen, S.G. et al. 1996. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[137]

Tanner, M. 2016. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. Annals of Internal Medicine. 165, 4 (Aug. 2016). DOI:https://doi.org/10.7326/ACPJC-2016-165-4-020.

[138]

Tao, L. et al. 2015. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine. 32, 7 (Jul. 2015), 907–919. DOI:https://doi.org/10.1111/dme.12711.

[139]

Umpierre, D. 2011. Physical Activity Advice Only or Structured Exercise Training and Association With HbA                              Levels in Type 2 Diabetes. JAMA. 305, 17 (May 2011). DOI:https://doi.org/10.1001/jama.2011.576.

[140]

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care: http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview.

[141]

Villani, M. et al. 2017. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine. 34, 9 (Sep. 2017), 1205–1211. DOI:https://doi.org/10.1111/dme.13379.

[142]

Vloemans, A.F. et al. 2017. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabetic Medicine. 34, 10 (Oct. 2017), 1470–1476. DOI:https://doi.org/10.1111/dme.13429.

[143]

Wanner, C. et al. 2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 323–334. DOI:https://doi.org/10.1056/NEJMoa1515920.

[144]

WHO 2011 Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/.

[145]

Yeh, J.S. et al. 2016. Obesity and Management of Weight Loss. New England Journal of Medicine. 375, 12 (Sep. 2016), 1187–1189. DOI:https://doi.org/10.1056/NEJMclde1515935.

[146]

Yki-Järvinen, H. et al. 2006. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 49, 3 (Mar. 2006), 442–451. DOI:https://doi.org/10.1007/s00125-005-0132-0.

[147]

Young, L.A. and Buse, J.B. 2014. GLP-1 receptor agonists and basal insulin in type 2 diabetes. The Lancet. 384, 9961 (Dec. 2014), 2180–2181. DOI:https://doi.org/10.1016/S0140-6736(14)61409-4.

[148]

Young-Hyman, D. et al. 2017. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140. Diabetes Care. 40, 2 (Feb. 2017), 287.1-287. DOI:https://doi.org/10.2337/dc17-er02.

[149]

Zaccardi, F. et al. 2016. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal. 92, 1084 (Feb. 2016), 63–69. DOI:https://doi.org/10.1136/postgradmedj-2015-133281.

[150]

Zinman, B. et al. 2011. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet. 377, 9769 (Mar. 2011), 924–931. DOI:https://doi.org/10.1016/S0140-6736(10)62305-7.

[151]

[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics.

[152]

2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 375, 18 (Nov. 2016), 1799–1802. DOI:https://doi.org/10.1056/NEJMc1611290.

[153]

2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375, 18 (Nov. 2016), 1797–1799. DOI:https://doi.org/10.1056/NEJMc1611289.

[154]

2015. Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care. 38, 8 (Aug. 2015), 1583–1591. DOI:https://doi.org/10.2337/dc15-0279.

[155]

4AD. Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes.

[156]

2015. Standards of Medical Care in Diabetes--2015: Summary of Revisions. Diabetes Care. 38, Supplement_1 (Jan. 2015), S4–S4. DOI:https://doi.org/10.2337/dc15-S003.

[157]

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.